Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune checkpoint inhibitor-related pneumonitis with atypical radiologic features in a patient with anti-aminoacyl-tRNA synthetase antibody.
Ichihara S, Ogino H, Yoneda H, Haji K, Kagawa K, Murakami K, Mima M, Aoi Y, Mitsuhashi A, Tsukazaki Y, Yabuki Y, Ozaki R, Sato S, Nokihara H, Nishioka Y. Ichihara S, et al. Among authors: mima m. Respir Med Case Rep. 2022 Dec 15;41:101797. doi: 10.1016/j.rmcr.2022.101797. eCollection 2023. Respir Med Case Rep. 2022. PMID: 36583061 Free PMC article.
Enhancer infestation drives tumorigenic activation of inactive B compartment in Epstein-Barr virus-positive nasopharyngeal carcinoma.
Mizokami H, Okabe A, Choudhary R, Mima M, Saeda K, Fukuyo M, Rahmutulla B, Seki M, Goh BC, Kondo S, Dochi H, Moriyama-Kita M, Misawa K, Hanazawa T, Tan P, Yoshizaki T, Fullwood MJ, Kaneda A. Mizokami H, et al. Among authors: mima m. EBioMedicine. 2024 Apr;102:105057. doi: 10.1016/j.ebiom.2024.105057. Epub 2024 Mar 14. EBioMedicine. 2024. PMID: 38490101 Free PMC article.
Discovery of novel indole derivatives as potent and selective inhibitors of proMMP-9 activation.
Nishikawa-Shimono R, Kuwabara M, Fujisaki S, Matsuda D, Endo M, Kamitani M, Futamura A, Nomura Y, Yamaguchi-Sasaki T, Yabuuchi T, Yamaguchi C, Tanaka-Yamamoto N, Satake S, Abe-Sato K, Funayama K, Sakata M, Takahashi S, Hirano K, Fukunaga T, Uozumi Y, Kato S, Tamura Y, Nakamori T, Mima M, Mishima-Tsumagari C, Nozawa D, Imai Y, Asami T. Nishikawa-Shimono R, et al. Among authors: mima m. Bioorg Med Chem Lett. 2024 Jan 1;97:129541. doi: 10.1016/j.bmcl.2023.129541. Epub 2023 Nov 10. Bioorg Med Chem Lett. 2024. PMID: 37952596
Structure-based lead optimization to improve potency and selectivity of a novel tetrahydroimidazo[1,2-a]pyridine-5-carboxylic acid series of heparanase-1 inhibitor.
Imai Y, Suzuki R, Wakasugi D, Matsuda D, Tanaka-Yamamoto N, Ohki Y, Mima M, Endo M, Tabata R, Matsuzawa H, Hasegawa Y, Kato S, Sugisaki M, Miyagawa H, Fujimoto N, Fukunaga T, Kato S, Takahashi T, Kakinuma H. Imai Y, et al. Among authors: mima m. Bioorg Med Chem. 2023 Oct 1;93:117460. doi: 10.1016/j.bmc.2023.117460. Epub 2023 Aug 26. Bioorg Med Chem. 2023. PMID: 37660465
Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY® compound, offers the potential advantage of mitigating the risk of immune complex-induced inflammation.
Kyuuma M, Kaku A, Mishima-Tsumagari C, Ogawa B, Endo M, Tamura Y, Ishikura KI, Mima M, Nakanishi Y, Fujii Y. Kyuuma M, et al. Among authors: mima m. Front Immunol. 2023 Apr 14;14:1149874. doi: 10.3389/fimmu.2023.1149874. eCollection 2023. Front Immunol. 2023. PMID: 37122706 Free PMC article.
99 results